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The role of sympathetic nerve activity in the changes in arterial blood
pressure and renal function caused by the chronic administration of NG-
nitro-L-arginine methyl ester (L-NAME), an inhibitor of nitric oxide
(NO) synthesis, was examined in sham and bilaterally renal denervated
rats. Several studies have demonstrated that sympathetic nerve activity is
elevated acutely after L-NAME administration. To evaluate the role of
renal nerve activity in L-NAME-induced hypertension, we compared the
blood pressure response in four groups (N = 10 each) of male Wistar-
Hannover rats weighing 200 to 250 g: 1) sham-operated vehicle-treated,
2) sham-operated L-NAME-treated, 3) denervated vehicle-treated, and
4) denervated L-NAME-treated rats. After renal denervation or sham
surgery, one control week was followed by three weeks of oral adminis-
tration of L-NAME by gavage. Arterial pressure was measured weekly
in conscious rats by a tail-cuff method and renal function tests were
performed in individual metabolic cages 0, 7, 14 and 21 days after the
beginning of L-NAME administration. L-NAME (60 mg kg-1 day-1)
progressively increased arterial pressure from 108 ± 6.0 to 149 ± 12
mmHg (P<0.05) in the sham-operated group by the third week of
treatment which was accompanied by a fall in creatinine clearance from
336 ± 18 to 222 ± 59 µl min-1 100 g body weight-1 (P<0.05) and a rise in
fractional urinary sodium excretion from 0.2 ± 0.04 to 1.62 ± 0.35%
(P<0.05) and in sodium post-proximal fractional excretion from 0.54 ±
0.09 to 4.7 ± 0.86% (P<0.05). The development of hypertension was
significantly delayed and attenuated in denervated L-NAME-treated
rats. This was accompanied by a striking additional increase in fractional
renal sodium and potassium excretion from 0.2 ± 0.04 to 4.5 ± 1.6% and
from 0.1 ± 0.015 to 1.21 ± 0.37%, respectively, and an enhanced post-
proximal sodium excretion compared to the sham-operated group. These
differences occurred despite an unchanged creatinine clearance and Na+
filtered load. These results suggest that bilateral renal denervation
delayed and attenuated the L-NAME-induced hypertension by promot-
ing an additional decrease in tubule sodium reabsorption in the post-
proximal segments of nephrons. Much of the hypertension caused by
chronic NO synthesis inhibition is thus dependent on renal nerve activity.
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Introduction
The endothelium is the major source of
nitric oxide (NO) which plays an important
role in local circulatory control (1,2). Un-
controlled hypertension with associated en-
dothelial damage increases cardiovascular
morbidity and mortality and leads to pro-
gressive renal functional impairment in es-
sential hypertension (3). Experimental mod-
els of renal disease with hypertension, in-
cluding renal failure in rats, normally require
nephrectomy and extirpation of tissue from
the contralateral kidney, renal infarction, or
the use of nephrotoxic drugs or chemicals to
produce significant hypertension (4,5). As a
result, extrapolation from such studies to
patients with essential hypertension who have
two normally functioning kidneys seems in-
appropriate. A better laboratory model is
therefore essential for an accurate under-
standing of the pathophysiological progres-
sion and renal involvement occurring in hy-
pertension.
Several studies have shown that short-
term administration of an NO synthase (NOS)
inhibitor results in a prompt increase in the
arterial pressure of rats, rabbits, and dogs (6-
8). The immediate increase in arterial pres-
sure mainly reflects an increased vascular
smooth muscle tone as a consequence of
decreased NO synthesis. Increases in sym-
pathetic nerve activity have been described
after acute inhibition of NO synthesis (6-
10), suggesting that neurogenic mechanisms
may contribute to the rise in arterial pres-
sure.
Chronic intravenous infusion of the NO
synthesis inhibitor NG-nitro-L-arginine meth-
yl ester (L-NAME) also causes sustained
hypertension in dogs and rats (11-13) associ-
ated with increased renal vascular resistance,
glomerular filtration rate and urinary sodium
excretion. Additionally, the natriuretic ef-
fects of arterial pressure on urinary sodium
excretion in anesthetized dogs have recently
been shown to be significantly attenuated
during L-NAME administration (14-16).
Although the precise mechanism by
which continued NO synthesis inhibition
induces chronic hypertension remains to be
identified, renal control of the fluid and elec-
trolyte balance is thought to play a dominant
role in the long-term control of arterial pres-
sure in both normal and pathophysiological
states (6-8,14). Renal sympathetic nerve ac-
tivity increases after inhibition of NO syn-
thesis (10,13) and the activation of these
nerves inhibits renal sodium excretion and
promotes renal renin secretion (11). How-
ever, the long-term changes in renal sodium
tubule handling associated with L-NAME-
induced hypertension in rats have not been
examined in detail. We hypothesized that
chronic L-NAME-induced hypertension may
result partly from sustained renal sympa-
thetic nerve activation and a consequent de-
crease in renal sodium excretion. To test this
hypothesis, we investigated the effects of
chronic oral administration of L-NAME on
the arterial pressure and tubule sodium han-
dling of renal denervated rats and their sham-
operated controls.
Material and Methods
The experiments were performed on male
Wistar-Hannover rats (200-250 g) allowed
free access to water and normal rat chow. To
examine the influence of renal denervation
during the administration of L-NAME the
rats were assigned randomly to one of four
groups (N = 10 each): 1) sham-operated ve-
hicle-treated, 2) sham-operated L-NAME-
treated, 3) denervated vehicle-treated, and
4) denervated L-NAME-treated rats. The
general guidelines established by the Decla-
ration of Helsinki (1964) for laboratory ani-
mals were followed throughout the study.
Experimental design
The experiments consisted of one control
week followed by three weeks of oral admin-
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istration of L-NAME (60 mg kg-1 day-1) or
vehicle by gavage. Arterial pressure was
estimated weekly in conscious, restrained
rats by the tail-cuff method using an
electrosphygmomanometer (Narco Bio-Sys-
tems, Austin, TX, USA). On the last day of
each week (control week (0) and 7, 14 and
21 days after beginning L-NAME adminis-
tration), the rats were weighed and housed in
individual metabolic cages to measure uri-
nary flow rate and protein excretion over a
14-h period. Renal function tests were also
performed.
Fourteen hours before the renal test, 60
mmol LiCl/100 g body weight was given by
gavage. The rats were subsequently housed
individually in metabolic cages with free
access to tap water but no food. The experi-
ment was performed at the same time in each
group of sham-operated (vehicle or L-
NAME-treated) and denervated (vehicle or
L-NAME-treated) rats. At 8:00 a.m., each
rat received a tap water load (5% of body
weight) by gavage followed by a second load
of the same volume 1 h later. Twenty min-
utes after the second load, spontaneously
voided urine was collected over a 2-h period.
The voided urine passed through the funnel
in the bottom of a cage into a graduated
centrifuge tube. At the end of the experi-
ment, blood samples were drawn by cardiac
puncture and the kidney was immediately
removed, decapsulated and weighed.
Renal denervation
After dorsal abdominal incisions, both
kidneys were exposed and surgically dener-
vated with the aid of a stereomicroscope in
rats anesthetized with pentobarbital sodium
(30-50 mg/kg, ip). Denervation was accom-
plished by cutting all visible nerves along the
renal artery and by stripping the nervous and
connective tissue passing along the course of
the renal artery and vein. Immediately there-
after, the renal vessels were wrapped with
cotton previously soaked in 10% (v/v) phe-
nol diluted with absolute ethanol (17). Sham-
operated rats underwent all of the surgical
procedures except that the renal artery was
left intact. The rats were used 1 week after
renal denervation.
Biochemical analysis
Plasma and urine sodium, potassium and
lithium concentrations were measured by
flame photometry, while the creatinine and
protein concentrations were determined spec-
trophotometrically by the alkaline picrate
and sulfosalicylic acid methods, respectively.
Statistics and calculations
The results are reported as means ± SEM
per 100 g body weight. Renal clearance (C)
was calculated by a standard formula (C =
UV/P) using the plasma creatinine and
lithium levels for each period. Creatinine
clearance was used to estimate glomerular
filtration rate and lithium clearance (CLi+)
was used to assess proximal tubule output.
Fractional sodium (FENa+) and potassium
(FEK+) excretions were calculated as CNa+/
CCr and CK+/CCr, respectively, where CNa+
and CK+ are the ion clearances and CCr is
the creatinine clearance. The fractional proxi-
mal (FEPNa+) and post-proximal (FEPPNa+)
sodium excretions were calculated as CLi+/
CCr x 100 and CNa+/CLI+ x 100, respec-
tively (18,19). Changes in fractional excre-
tion were estimated using the values from
sham-operated rats. Statistical analysis of
the data was performed by one-way analysis
of variance for repeated measurements. When
the results were significant, Bonferronis
contrast test was used to determine the ex-
tent of the differences. A P value <0.05 was
considered to indicate significance.
Results
Figures 1 and 2 show the effects of L-
NAME treatment and renal denervation on
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was similar in all groups during the first
week but increased in sham-operated L-
NAME-treated rats from the second week
onwards (Figure 1). By the end of the third
week, proteinuria was significantly higher in
these rats than in the other three groups.
There were no significant differences in daily
solid rat chow intake (median: 22.7 g, range:
15.3 to 31.2 g) or serum potassium, sodium
and lithium levels between sham-operated
rats and the other groups (Table 1).
Basal blood pressure did not differ sig-
nificantly among the four groups. After 1
week, arterial pressure was significantly in-
creased in sham-operated L-NAME-treated
rats compared with the other groups and
reached 149 ± 12 mmHg by week 3 com-
pared to 108 ± 6.0 mmHg in sham-operated
vehicle-treated rats (P<0.05) (Figure 2). Ar-
terial pressure did not change significantly
in the other groups during the three weeks of
the study (Figure 1).
Urinary flow rates did not differ signifi-
cantly among the groups during the study of
renal tubule sodium handling. Glomerular
filtration rate estimated by CCr decreased
significantly from 336 ± 18 to 222 ± 59 µl
min-1 100 g body weight-1 in sham-operated
L-NAME-treated rats and from 329 ± 20.3 to
250 ± 22 µl min-1 100 g body weight-1 in
denervated L-NAME-treated animals (Fig-
ure 2). Creatinine clearance dropped tran-
siently in denervated rats between weeks 1
and 2 after renal denervation but returned to
basal levels by the third week. Creatinine
clearance was 315 ± 19 µl min-1 100 g body
weight-1 in the vehicle-infused rats and re-
mained unchanged throughout the experi-
ment. Basal renal fractional sodium and po-
tassium excretion did not differ among the
experimental groups. L-NAME significantly
increased FENa+ and FEK+ excretion from 7
to 21 days post-treatment (Figure 2) and this
increase was accompanied by a significant
increase in post-proximal sodium excretion
compared to the sham-operated vehicle-
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Figure 1 - Effect of oral L-NAME administration on body weight, proteinuria, mean arterial
pressure and renal creatinine clearance in sham-operated rats compared to bilaterally renal
denervated (DNx) rats. The data are reported as the mean ± SEM for 10 rats per group.
*P<0.05 compared to the sham-operated vehicle-treated or sham-operated L-NAME-treated
rats (ANOVA and Bonferroni’s contrast test).
Table 1 - Effect of the oral administration of vehicle (group I, GI), or L-NAME (GII) to
sham-operated rats on body weight, renal weight and serum sodium, potassium and
lithium levels compared to similar vehicle (GIII) or L-NAME (GIV) administration to
bilaterally renal denervated rats.
The data are reported as the means ± SEM for 10 rats per group. There were no
statistically significant differences in the parameters studied (ANOVA and Bonferroni’s
contrast test).
Groups Body Renal Liquid intake Na+ K+ Li+
weight (g) weight (g) (ml) (mM) (mM) (µM)
GI 300 ± 15 1.46 ± 0.05  34.9 ± 0.9 143 ± 0.9 3.7 ± 0.1 107 ± 5.0
GII 289 ± 16 1.40 ± 0.05 34.8 ± 0.5 142 ± 1.2 4.5 ± 0.1 117 ± 6.0
GIII 291 ± 19 1.33 ± 0.05 35.7 ± 0.7 143 ± 0.4 4.4 ± 0.1 109 ± 8.0
GIV 302 ± 14 1.37 ± 0.06 33.8 ± 0.9 145 ± 0.7 4.3 ± 0.2 110 ± 7.2
renal function and arterial blood pressure.
All rats survived and were clinically healthy
up to the 21st day of the study. Although all
groups gained weight during the study, the
gain in L-NAME-treated rats tended to level
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curred despite a significant fall in CCr (Fig-
ure 1). Although CCr decreased transiently
between 7 and 14 days, urinary sodium and
potassium excretion was unchanged in renal
denervated rats compared to basal values
and sham-denervated rats.
The high urinary sodium and potassium
excretion observed in sham-operated L-
NAME-treated rats was enhanced by bilat-
eral renal denervation after 7 to 21 days of L-
NAME treatment. This enhanced fractional
excretion was associated with a significant
increase in proximal and post-proximal so-
dium excretion compared to the other groups
(Figure 2). As also observed in the L-NAME-
treated group, the rise in ion excretion was
associated with a significant fall in CCr.
Discussion
The present experiments tested the hypo-
thesis that the arterial hypertension induced
by NOS inhibition is related, at least in part,
to changes in renal nerve activity and renal
sodium excretion. Our results agree with
previous studies which have demonstrated
that long-term oral administration of L-
NAME results in a marked and sustained
rise in arterial blood pressure associated with
an increase in urinary sodium excretion
(7,13,14,20). In addition, NOS inhibition
enhanced urinary sodium excretion by in-
creasing post-proximal tubule sodium rejec-
tion despite a decrease in glomerular filtra-
tion rate (Figure 1) and in the proportion of
sodium load filtered.
The inhibition of NO synthesis may in-
fluence tubular reabsorption by a direct ef-
fect on tubular sodium transport or by hemo-
dynamically mediated mechanisms involv-
ing a reduction in medullary blood flow or a
rise in renal interstitial hydrostatic pressure
(21,22). In support of a direct action of NO is
the study by Stoos et al. (23) which showed
that NO directly inhibited sodium transport
in cultured cortical collecting duct cells.



































Figure 2 - Effect of oral L-NAME administration on fractional sodium (FENa+) and potassium
(FEK+) excretion, and fractional proximal (FEPNa+) and post-proximal (FEPPNa+) tubule
sodium excretion in sham-operated rats compared to bilaterally renal denervated (DNx)
rats. The data are reported as the mean ± SEM for 10 rats per group. *P<0.05 compared to
the sham-operated vehicle-treated or sham-operated L-NAME-treated animals (ANOVA
and Bonferroni’s contrast test).
that NOS inhibition decreased papillary
plasma flow. These changes in intrarenal
hemodynamics may play an important role
in mediating the altered sodium handling
induced by L-NAME.
Previous studies which examined the ef-
fects of systemic NOS inhibition on sodium
excretion have yielded mixed results per-
haps because of differences in the experi-
mental methods and doses of L-NAME used,
type of anesthesia, and the activity of endog-
enous vasoconstrictor systems. These fac-
tors could influence the extent to which re-
nal perfusion pressure and renal vascular
resistance responded to the inhibition of NO
synthesis, thus affecting sodium excretion.
Baylis et al. (15) reported that bolus intrave-
nous injection of NG-monomethyl arginine
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tion whereas bolus injection of L-NAME
(10 mg) did not effect natriuresis. Lahera et
al. (16) examined the effect of different doses
of L-NAME on natriuresis. In rats receiving
1 mg kg-1 min-1, an anti-natriuretic response
occurred with no changes in mean arterial
pressure, renal plasma flow or glomerular
filtration rate. In contrast, the infusion of 50
mg kg-1 min-1 significantly increased arterial
pressure and was accompanied by an early
progressive fall in renal blood flow and glo-
merular filtration with no change in renal
sodium excretion.
These results suggest that the inhibition
of NOS can directly and transiently enhance
sodium reabsorption in post-proximal neph-
ron segments. However, at larger doses such
as that used in our experiments, L-NAME
produced increases in arterial pressure that
overrode the initial anti-natriuretic effect. In
agreement with this observation, Madrid et
al. (20) reported that a high dose of L-NAME
increased UNaV and FENa+ in rats, whereas
a low dose of L-NAME reduced renal so-
dium excretion and blunted pressure natri-
uresis only in rats with innervated kidneys.
NO synthase inhibitors have been re-
ported to decrease glomerular filtration rate
in some studies (8), but not in others (14).
Although neither renal blood flow nor renal
vascular resistance was measured in the pres-
ent study, glomerular filtration rate decreased
following L-NAME administration, suggest-
ing afferent arteriole vasoconstriction. Pre-
vious studies have demonstrated that L-
NAME decreases renal blood flow without
changing glomerular filtration (24). These
observations imply that NO inhibition may
selectively increase postglomerular renal vas-
cular resistance.
The precise mechanism underlying the
chronic hypertension induced by NOS inhi-
bition has not been identified. The long-term
control of arterial pressure is thought to be
dominated by the renal control of fluid and
electrolyte balance (25,26). However, as
pointed out above, the sodium balance has
been reported to be near normal (27) or even
positive (28) during chronic administration
of NOS inhibitors, despite a significant el-
evation in renal perfusion pressure.
The present findings show that renal de-
nervation markedly delayed and possibly at-
tenuated the L-NAME-induced increase in
arterial pressure (Figure 1) associated with
an additional rise in post-proximal sodium
rejection. Thus, chronic L-NAME-induced
hypertension in renal denervated rats may be
dependent on an anti-natriuretic neural ef-
fect that blunts the renal pressure natriuresis
induced by the rise in blood pressure. Com-
plete renal denervation delays the rise in
blood pressure in other rat models of hyper-
tension, including spontaneously hyperten-
sive and New Zealand rat strains and hyper-
tension induced by angiotensin-II (29). How-
ever, negative results have been reported for
salt-sensitive Dahl rats and the effect of re-
nal denervation in preventing hypertension
in the DOCA-salt and the one-kidney, one-
clip models is controversial (29).
The salient findings of the present study
suggest that the increase in arterial pressure
after NOS inhibition is partly mediated by
renal nerve activity. Sakuma et al. (30)
showed that intravenous administration of
the NO synthesis inhibitor increased renal
sympathetic nerve activity. Spinal section-
ing but not by vagotomy or sinoartic barore-
ceptor denervation abolished this effect. The
injection of NO synthesis inhibitors intracis-
ternally (31) and directly into the nucleus
tractus solitarius (32) and rostral ventrolat-
eral medulla (33) also increases arterial pres-
sure and renal sympathetic nerve activity.
NO may be involved in brain stem regulation
of sympathetic nerve activity and NO inhibi-
tors may influence the renal control of so-
dium excretion and arterial pressure via this
pathway.
Although the rationale for renal denerva-
tion has generally been to interrupt sympa-
thetic nerve activity directed at the kidney,
denervation of the renal plexus also deprives
353
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the kidney of its sensory innervation. Selec-
tive renal afferent nerves may have remark-
ably widespread effects on the renorenal
sympathetic reflexes and urinary sodium
excretion (34,35). Selective renal afferent
denervation attenuates hypertension in the
one-kidney, one-clip model and causes a
small reduction in blood pressure in sponta-
neously hypertensive rats (35). However,
selective afferent denervation had no effect
on the development of hypertension in spon-
taneously hypertensive rats during renal wrap
hypertension or during hypertension caused
by the infusion of norepinephrine into the
renal artery (35). Since our experiments were
not specifically designed to distinguish be-
tween the effects of efferent and afferent
renal denervation, we cannot discount an
influence of afferent renal nerves on our
results. Although the precise mechanism re-
sponsible for the subsequent rise in arterial
pressure in renal denervated rats treated with
L-NAME is still not clear, our study suggests
that bilateral renal denervation delayed and
possibly attenuated L-NAME-induced hy-
pertension by promoting an additional de-
crease of tubule sodium reabsorption in the
post-proximal segments of nephrons. Much
of the hypertension caused by chronic NO
synthesis inhibition is thus dependent on
renal nerve activity.
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